Adoptive cell transfer methods
OwnerStephen Marcusinventor
Life of this patent
Estimating the term…
Abstract
Methods and compositions are presented for mobilizing hematopoietic stem cells (HSC) and for mobilizing T lymphocytes from the bone marrow and other compartments; use of the mobilized HSCs for HSC transplantation and mobilized T lymphocytes for T cell immunotherapy; for enhancing engraftment of transplanted HSCs and transferred T cells; and for enhancing recovery of hematopoietic system function following HSC transplantation or for enhancing engraftment and/or persistence of T cells following transfer for T cell immunotherapy.
Claims56
A method of obtaining hematopoietic stem cells (HSC) from a donor, comprising:
- administering to a donor subject a CXCL12-interacting heparinoid in an amount effective to mobilize HSC cells;
- and
- isolating the HSC cells from the peripheral blood of the donor.
2-4. (canceled)
8-11. (canceled)
(canceled)
(canceled)
19-24. (canceled)
26-28. (canceled)
(canceled)
A method of hematopoietic stem cell (HSC) transplantation, comprising:
- (a) administering to a HSC donor an amount of a CXCL12-interacting heparinoid effective to mobilize HSC cells in the bone marrow;
- (b) isolating the HSC cells from the donor;
- and
- (c) transplanting the HSC cells into a recipient subject in need of HSC transplantation.
(canceled)
A method of improving hematopoietic stem cell (HSC) engraftment in an HSC transplant recipient, comprising:
- administering to a recipient subject in need of HSC transplantation a CXCL12-interacting heparinoid in an amount effective to enhance engraftment of graft HSC.
40-43. (canceled)
45-52. (canceled)
(canceled)
58-102. (canceled)
A method of obtaining T lymphocytes for T cell immunotherapy, comprising:
- administering to a donor a CXCL12-interacting heparinoid in an amount effective to increase in the peripheral blood of the donor the concentration of T lymphocytes that have at least one desired phenotype;
- and
- obtaining T lymphocytes from the donor's peripheral blood.
110-113. (canceled)
115-133. (canceled)
A method of conditioning a T cell immunotherapy recipient to enhance the establishment or grafting of donor T cells in the recipient, comprising:
- administering a CXCL12-interacting heparinoid to the recipient in an amount and for a period sufficient to deplete the recipient's bone marrow of cellular elements, at a time when depleting the recipient's bone marrow of cellular elements enhances establishment or grafting of donor T lymphocytes in the recipient.
137-140. (canceled)
142-166. (canceled)
170-180. (canceled)
Dependencies are inferred from the claim text.